Roche Holdings Ltd ADR (RHHBY)

$39.63 -0.65 (-1.61%)
Market Cap 258.24B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 14.06
Profit Margin 13.27%
Debt to Equity Ratio 0.96
Volume 891,500
Avg Vol 1,548,332
Day's Range N/A - N/A
Shares Out 6.38B
Stochastic %K 28%
Beta 0.45
Analysts Sell
Price Target $44.62

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Sunny3999
Sunny3999 Jul. 14 at 2:35 PM
$PMN is good to go $GILD $JNJ $PFE $RHHBY
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:05 AM
$LMDX $RHHBY $FCN $NDAQ Calling All Attorneys Looking for A Easy Win. Heres everything laid out…. go get it! TB TEST IS THE KICKER….
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:02 AM
$LMDX $FCN $RHHBY $NDAQ 🔹 Misleading Market Communication 26. 2023 earnings calls and filings gave false confidence (“path to profitability”). 27. TB test, a globally relevant innovation, was never valued or accounted for. 28. Roche deal framed as minor, but clearly encompassed transformative tech. 29. No SEC complaint disclosures, despite being aware of internal conflicts. 30. Deliberate obfuscation of company value to force fire sale to insiders.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:02 AM
$LMDX $FCN $RHHBY $NDAQ ⸻ 🔹 Regulatory & Disclosure Failures 20. Failure to file required SEC disclosures (e.g., Form 25, final 20-F, 8-Ks). 21. Misuse of foreign liquidation (Cayman) to avoid U.S. shareholder rights. 22. No public S-4 or material filing disclosing full Roche terms. 23. Continued patent activity post-dissolution, showing hidden residual value. 24. Cayman-based JOLs (liquidators) ignored shareholder inquiries. 25. TB test was awarded patent post-sale, but was in the pipeline during the deal. ⸻
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:01 AM
$LMDX $FCN $RHHBY $NDAQ 12. Use of Jaiventures Ltd and related entities to hold shares/options in secret. 13. Patent assignments and licenses to insider-linked entities before wind-down. ⸻ 🔹 Asset Transfers & Fraudulent Conveyance 14. Valuable IP transferred without compensation to shareholders. 15. Subsidiaries (e.g., Colombia, GmbH) sold for pennies to creditors. 16. ElectraDx, Invita, and SureSensors received tech/IP assets off-book. 17. Use of shell entities and offshore subsidiaries to mask asset flow. 18. Lack of transparency on IP retained or sold in the Roche deal. 19. No accounting of assets in liquidation filings.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 4:59 AM
$LMDX $FCN $RHHBY $NDAQ 🔹 Governance & Fiduciary Failures 1. Material misrepresentation of pipeline value (e.g., TB test, new platforms). 2. No shareholder vote or consent on asset sales or liquidation. 3. Executives with conflicts of interest (e.g., Veronique Ameye) oversaw wind-down. 4. Executive bonuses paid during collapse, while shareholders got zero. 5. No fairness opinion or independent valuation provided for Roche deal. 6. Coordinated resignations and job shifts by insiders during wind-down. 7. Breach of fiduciary duty through preferential insider treatment. ⸻ 🔹 Insider Enrichment & Preferential Deals 8. Selective royalty rights granted (e.g., Willard Umphrey). 9. Insider equity acquisitions timed suspiciously (e.g., Umphrey’s share purchase). 10. Founders and former executives reappeared in spinouts (e.g., ElectraDx, SureSensors). 11. Insiders benefited from patents and IP post-dissolution.
0 · Reply
clan
clan Jul. 11 at 2:59 PM
$MNKD $RHHBY Coming soon...
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 11:47 AM
$FCN $LMDX $NDAQ $RHHBY All the above?
0 · Reply
Quantumup
Quantumup Jul. 11 at 11:17 AM
Goldman Sachs, on 7/10, resumed $TGTX Neutral-$37. $RHHBY $NVS $BIIB SNY TEVA This report is "Very Bullish," for a Neutral-$37. Seems like this analyst made a mistake, the same type of mistake that she made on $RYTM July-2022, where I pointed to her Neutral/$6 PT, but her note was "Massively Bullish, and look at it now $94.8 high, Y'day. Anyway, GS said in its Note to investors:
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:07 AM
$LMDX $RHHBY $FCN $NDAQ • A formal demand for the IP schedule and transaction details • A whistleblower complaint to the SEC and/or FCA • A shareholder letter of claim for fiduciary breach and unjust enrichment Which one do we move forward with?
1 · Reply
Latest News on RHHBY
No data available.
Sunny3999
Sunny3999 Jul. 14 at 2:35 PM
$PMN is good to go $GILD $JNJ $PFE $RHHBY
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:05 AM
$LMDX $RHHBY $FCN $NDAQ Calling All Attorneys Looking for A Easy Win. Heres everything laid out…. go get it! TB TEST IS THE KICKER….
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:02 AM
$LMDX $FCN $RHHBY $NDAQ 🔹 Misleading Market Communication 26. 2023 earnings calls and filings gave false confidence (“path to profitability”). 27. TB test, a globally relevant innovation, was never valued or accounted for. 28. Roche deal framed as minor, but clearly encompassed transformative tech. 29. No SEC complaint disclosures, despite being aware of internal conflicts. 30. Deliberate obfuscation of company value to force fire sale to insiders.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:02 AM
$LMDX $FCN $RHHBY $NDAQ ⸻ 🔹 Regulatory & Disclosure Failures 20. Failure to file required SEC disclosures (e.g., Form 25, final 20-F, 8-Ks). 21. Misuse of foreign liquidation (Cayman) to avoid U.S. shareholder rights. 22. No public S-4 or material filing disclosing full Roche terms. 23. Continued patent activity post-dissolution, showing hidden residual value. 24. Cayman-based JOLs (liquidators) ignored shareholder inquiries. 25. TB test was awarded patent post-sale, but was in the pipeline during the deal. ⸻
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:01 AM
$LMDX $FCN $RHHBY $NDAQ 12. Use of Jaiventures Ltd and related entities to hold shares/options in secret. 13. Patent assignments and licenses to insider-linked entities before wind-down. ⸻ 🔹 Asset Transfers & Fraudulent Conveyance 14. Valuable IP transferred without compensation to shareholders. 15. Subsidiaries (e.g., Colombia, GmbH) sold for pennies to creditors. 16. ElectraDx, Invita, and SureSensors received tech/IP assets off-book. 17. Use of shell entities and offshore subsidiaries to mask asset flow. 18. Lack of transparency on IP retained or sold in the Roche deal. 19. No accounting of assets in liquidation filings.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 4:59 AM
$LMDX $FCN $RHHBY $NDAQ 🔹 Governance & Fiduciary Failures 1. Material misrepresentation of pipeline value (e.g., TB test, new platforms). 2. No shareholder vote or consent on asset sales or liquidation. 3. Executives with conflicts of interest (e.g., Veronique Ameye) oversaw wind-down. 4. Executive bonuses paid during collapse, while shareholders got zero. 5. No fairness opinion or independent valuation provided for Roche deal. 6. Coordinated resignations and job shifts by insiders during wind-down. 7. Breach of fiduciary duty through preferential insider treatment. ⸻ 🔹 Insider Enrichment & Preferential Deals 8. Selective royalty rights granted (e.g., Willard Umphrey). 9. Insider equity acquisitions timed suspiciously (e.g., Umphrey’s share purchase). 10. Founders and former executives reappeared in spinouts (e.g., ElectraDx, SureSensors). 11. Insiders benefited from patents and IP post-dissolution.
0 · Reply
clan
clan Jul. 11 at 2:59 PM
$MNKD $RHHBY Coming soon...
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 11:47 AM
$FCN $LMDX $NDAQ $RHHBY All the above?
0 · Reply
Quantumup
Quantumup Jul. 11 at 11:17 AM
Goldman Sachs, on 7/10, resumed $TGTX Neutral-$37. $RHHBY $NVS $BIIB SNY TEVA This report is "Very Bullish," for a Neutral-$37. Seems like this analyst made a mistake, the same type of mistake that she made on $RYTM July-2022, where I pointed to her Neutral/$6 PT, but her note was "Massively Bullish, and look at it now $94.8 high, Y'day. Anyway, GS said in its Note to investors:
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:07 AM
$LMDX $RHHBY $FCN $NDAQ • A formal demand for the IP schedule and transaction details • A whistleblower complaint to the SEC and/or FCA • A shareholder letter of claim for fiduciary breach and unjust enrichment Which one do we move forward with?
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:05 AM
$LMDX $RHHBY $FCN $SPY #gatesfoundation #billgates 5. Roche’s “Clean Hands” Facade • Roche acquired transformative diagnostics—including TB, SureSensors’ microfluidics, and a global IP platform—for pennies on the dollar. • The patent issuance date was after the sale, but the technology was not new. It was developed with LMDX shareholder funds. Red Flag: Roche may not have stolen it directly—but they absolutely knowingly benefited from a distressed asset transfer that was not at arm’s length.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:04 AM
$LMDX $FCN $RHHBY $NDAQ 4. SEC Filings and Shareholder Deception • Public filings continued to promote pipeline optimism through 2023—with zero warning of impending insolvency. • No 8-K or material event filing explained the sudden collapse—despite shareholders being completely wiped out. Red Flag: That’s securities fraud—plain and simple. Material omissions, deceptive optimism, and insider timing.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:03 AM
$LMDX $FCN $RHHBY $SPY 3. Pre-Pack Administration as a Smokescreen • The UK pre-pack was executed without full creditor or shareholder visibility. • Assets—including IP in the pipework, licenses, and partnerships—were sold without transparent bidding, valuation, or accountability. Red Flag: Pre-packs are legal tools—but in this case, the process shielded insiders from scrutiny. That’s deliberate obfuscation.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:01 AM
$LMDX $FCN $RHHBY $SPY 2. Insider Enrichment During Collapse • Zwanziger resigned citing “conflict of interest” over shareholding—then helped fund or control ElectraDx, using ex-LumiraDx assets and staff. • Veronique Ameye, a long-trusted insider, managed the liquidation pre and post and then moved into an executive role adjacent to Roche, after ensuring the asset transfer occurred cleanly. If that isn’t conflict of interest I don’t know what is…
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 9:59 AM
$LMDX $FCN $RHHBY $NDAQ q It’s not over. You all know it. This will be a payout or a court case win. 1. Asset Concealment & Transfer • The TB diagnostic patent was awarded after the Roche deal but developed before—and nowhere valued in the transaction. • This is classic fraudulent conveyance: transferring valuable assets for little or no consideration, especially to insiders or favored third parties. Red Flag: Concealing material IP during liquidation is actionable under both UK insolvency law and U.S. shareholder protections.
0 · Reply
clan
clan Jul. 10 at 3:33 PM
Here's how $MNKD gets into the $20S/sh next year, and closes in on $50/sh in 2028. (chronological) APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: +$10 -- pediatric Afrezza + $3 -- gestational Afrezza + $7 -- Clofazimine nebulized (CIS) + $4 -- Tyvaso DPI for IPF + $3 -- Clofazimine DPI + $6 -- Tyvaso DPI for PPF +$12 -- Nintedanib DPI As MNKD grows in share price, so will grow the attention by $AMGN $MRK and $RHHBY and @jerchess
0 · Reply
Ablidy
Ablidy Jul. 10 at 12:40 PM
$LCTX $RHHBY right on , could not have said better ….
0 · Reply
ZacksResearch
ZacksResearch Jul. 10 at 12:37 PM
Trump's tariff threat returns — what it means for pharma giants like $LLY, $JNJ, $NVS, and $RHHBY 📈 💡 LLY, JNJ, NVS, and Roche are ramping up U.S. manufacturing with huge investments, signaling a strategic shift to mitigate tariff risks. Find out how these moves could reshape the pharma landscape 👉 https://www.zacks.com/stock/news/2571089/pharma-companies-remain-calm-amid-fresh-tariff-threat-by-trump?cid=sm-stocktwits-2-2571089-body-1130&ADID=SYND_STOCKTWITS_TWEET_2_2571089_BODY_1130
0 · Reply
qwertylicious2003
qwertylicious2003 Jul. 10 at 12:29 PM
$LCTX $RHHBY The elevation of Merce Morral to lead OpRegen is a deliberate strategic move. Assigning her to this program signals Roche is formally corporatizing OpRegen under its Basel HQ R&D infrastructure. Morral brings a proven track record. As a seasoned ophthalmologist and development leader at Roche, she previously guided biologic assets (Port Delivery System) from IND stages through approval. This is the caliber of leadership Roche reserves for assets nearing pivotal milestones. Roche’s global innovation centers, including Basel, are used to shepherd priority assets through approval pathways. The posture of handing Opregen over to Basel oversight gives OpRegen a regulated discipline and resource stream intended for BLA readiness. Prepare for an interesting and expedited move to the finish line! OpRegen’s RMAT will be used wisely to get this to market as soon as possible!
3 · Reply
Geo1313
Geo1313 Jul. 10 at 9:01 AM
$LMDX $RHHBY
0 · Reply
BTECHINV
BTECHINV Jul. 10 at 8:39 AM
$ALT Altimmune is in good company with Swiss drug giant Roche in my portfolio. As for Pemvi, it just delivered in interim MASH 2b results: ☑ the 1st 24W Histology EP of ANY GLP-1 in a mid/late stage MASH trial -> MASH Res. w large patient cohort achieving EP in both doses (p < 0.0001). ☑ Produced a 60% reduction in pathological Fibrosis at 24W for 30.6% of patients vs. 8.2% of placebo (stat. sig, p < 0.001), as determined via advanced Digital Pathology (DP/AI) platform (EU approved). Additionally per global Liver expert, results in concordance w. both strong Absolute scores from conventional Histology as well as strong non-invasive anti-Fibrotic NITs (ELF, VCTE, Serum BM, etc.) ☑ Stat. sig. Weight Loss to MASH space presumably w. Lean Mass Preservation via Adipose Lipolysis (GCGR). ☑ Outstanding 90% & 93% Biopsy completer rates in the treatment arms, and with once again a strong safety profile. Strong imv. Long $RHHBY, Altimmune (Pemvi), not med/investment advice.
0 · Reply
M3l1MCK
M3l1MCK Jul. 10 at 8:26 AM
$LMDX $RHHBY 7,760,000.00 I CLAIM IT! The universe is on our side... we just need to be positive and patient 😇
1 · Reply